Vesicants in Chemotherapy
Key Points
- Vesicants are chemotherapy drugs that cause severe tissue necrosis and ulceration if they leak out of the vein (extravasation) into surrounding tissue.
- Key vesicants include: doxorubicin (Adriamycin), vincristine, vinblastine, nitrogen mustard, paclitaxel, and epirubicin.
- Prevention requires a patent IV access, slow infusion rates, and vigilant site monitoring throughout administration.
- If extravasation is suspected: stop infusion immediately, do NOT flush, and follow institutional extravasation protocol.
- Vesicant drugs should be administered via a central venous access device (CVAD) when available — peripheral access is high-risk.
Definition and Mechanism
Vesicants are a class of chemotherapy agents with the chemical property of causing blistering and necrosis when they contact tissue outside the vascular system. When vesicants extravasate, they:
- Bind to cellular DNA and proteins in surrounding tissue
- Continue to cause cell death as the drug is slowly absorbed
- Produce progressive ulceration that may take weeks to months to heal
- In severe cases, cause tendon and nerve damage requiring surgical debridement or skin grafting
Vesicant vs. Irritant vs. Non-Vesicant
| Category | Tissue Effect | Examples |
|---|---|---|
| Vesicant | Tissue necrosis, blistering, ulceration | Doxorubicin, vincristine, epirubicin, nitrogen mustard, paclitaxel |
| Irritant | Local inflammation, burning, pain without necrosis | Carboplatin, etoposide, fluorouracil |
| Non-vesicant | Minimal local tissue effect | Cyclophosphamide, methotrexate |
Common Vesicant Drugs
| Drug | Class | Notes |
|---|---|---|
| Doxorubicin (Adriamycin) | Antitumor antibiotic | High risk; “Red Devil” — red coloration |
| Vincristine | Vinca alkaloid | Peripheral neuropathy also a risk |
| Vinblastine | Vinca alkaloid | Severe extravasation injury |
| Epirubicin | Antitumor antibiotic | Similar to doxorubicin |
| Paclitaxel (Taxol) | Antimitotic | Requires special diluent; vesicant risk |
| Nitrogen mustard (mechlorethamine) | Alkylating agent | Extreme tissue injury; early antidote needed |
Nursing Assessment
NCLEX Focus
Nurses must be certified to administer chemotherapy. Constant vigilance at the infusion site is the most critical prevention strategy. Any sign of extravasation — pain, swelling, redness, resistance to infusion — requires immediate action.
- Assess IV patency before starting vesicant infusion — aspirate for blood return, flush with saline
- Assess site at frequent intervals during infusion (every 5-15 minutes for peripheral access)
- Assess for symptoms of extravasation: pain, burning, stinging, swelling, redness, skin color change at site
- Assess for resistance to infusion flow — reduced flow may indicate infiltration
Prevention Strategies
- Administer vesicants through central venous access device (CVAD) when possible — PICC, port, or central line
- When peripheral access must be used:
- Use largest possible vein — antecubital or forearm veins preferred
- Avoid hands, wrists, and antecubital areas with poor visibility
- Use new IV site — do not administer through same-day blood draw site
- Infuse vesicants slowly per protocol (rate/minute infusion, not bolus)
- Check blood return before each push dose; do not proceed if blood return is absent
Extravasation Response Protocol
Extravasation Emergency
Extravasation of a vesicant is a nursing emergency. Delayed response increases the area of tissue necrosis.
Immediate Actions:
- Stop infusion immediately — do not flush line (may force drug deeper into tissue)
- Do NOT remove the IV needle — aspirate residual drug through the existing access first
- Aspirate as much of the drug as possible through the catheter
- Notify provider immediately
- Document the event: time, site location, estimated amount infiltrated, symptoms
Subsequent Actions (follow institutional protocol):
- Apply dry cold compress (for most vesicants) to limit drug dispersion — exception: vinca alkaloids require warm compress
- Administer antidote if available:
- Doxorubicin, epirubicin → Totect (dexrazoxane) IV antidote
- Vinca alkaloids → Hyaluronidase (subcutaneous injection around site) + warm compresses
- Mechlorethamine → Sodium thiosulfate injection
- Photograph site and reassess every 15-30 minutes for progression
- Surgical consult may be required for severe necrosis
Related Concepts
- peripheral-iv-therapy-complications — Extravasation context within IV therapy risks.
- cvad-indications-and-device-selection — Central access preferred for vesicant administration.
- leukopenia-and-neutropenia — Common concurrent complication of myelosuppressive chemotherapy.
- hematopoietic-growth-factors — Growth factors used to support bone marrow after chemotherapy.
- hypersensitivity-types-and-anaphylaxis-response — Chemotherapy infusion reactions and anaphylaxis management.
- blood-sampling-modalities-and-preanalytical-safety — Vascular access and specimen collection safety.
Self-Check
- A patient receiving doxorubicin via peripheral IV reports sudden burning at the site. The infusion flow has slowed. What are the priority nursing actions?
- Why should the IV catheter remain in place during initial extravasation response?
- Why are vinca alkaloids treated with warm compresses while most other vesicants receive cold compresses?